Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
about
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working partyThe Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder CancerAutophagy and urothelial carcinoma of the bladder: A reviewActive surveillance for nonmuscle invasive bladder cancerComparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerBacille-Calmette-Guerin non-responders: how to manageManagement of carcinoma in situ of the bladder: best practice and recent developmentsHexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladderGuideline-based management of non-muscle invasive bladder cancerApproaching the optimal transurethral resection of a bladder tumorThe Yin and Yang of Toll-like receptors in cancerDefining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseThe use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinomaUpper tract urothelial carcinoma: Paradigm shift towards nephron sparing managementCurrent efforts and future prospects in the development of live mycobacteria as vaccinesBladder cancer biomarker discovery using global metabolomic profiling of urineMultimodal 3D cancer-mimicking optical phantom.Urethral-sparing histotripsy of the prostate in a canine model.Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive DiseaseA Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer CellsClinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancerNatural biology and management of nonmuscle invasive bladder cancer.Update on the management of non-muscle invasive bladder cancer.MicroRNAs as biomarkers associated with bladder cancer.Urine-based assays for the detection of bladder cancer.Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.A systematic review of regional hyperthermia therapy in bladder cancer.Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer.mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder CancerCanadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.Patterns of care for early stage bladder cancer.The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinMulti-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin
P2860
Q24648407-EA07FD3B-CF10-4894-9191-387FCCE55063Q26738516-537B2CAD-6C2F-4D6A-8EAD-E52FFFDBB9F2Q26744142-A307A387-0AE0-4863-BC2E-FEF24047148DQ26744158-E8875477-2448-4942-ADC4-F93BBECC2113Q26744756-3C4579E0-DCD3-47CB-8A98-74741C8012DAQ26770422-B5846597-A0A9-474A-8439-D8A39BF2B04FQ26773679-F270785B-51A2-4A1D-B8F6-19BA4AB4D145Q26775772-66CCB305-5FE8-4B1C-B5A3-D0D29F6C8EF2Q26775775-EF6AE3F7-162C-45F4-99DB-5BA985154562Q26775975-7E2D3A64-1A03-4277-B850-8E7574414599Q26829828-7F703DD6-6C40-4144-B054-ACF8C6D00F08Q26851526-470235C8-E29B-4C66-9589-2B23FE458901Q26852084-2FA1D684-F674-4D8A-95ED-AA3E80850F04Q27011829-D7E899FD-EEB3-405A-BF55-D5175FD01143Q27692027-C880CB33-7ACF-4C77-AEFF-0513F86F47D4Q28066806-B2DE0190-A3C0-4B7A-B4B5-FAB08C63845AQ28087077-EC8879CF-9246-47C1-8DB8-E41ECA02A404Q28542873-BA3E7405-7A48-40DE-BE6B-3661486F5AEFQ30388394-C012F427-317B-4955-A347-B857F10063C5Q30450128-4DD749FA-53A4-4C38-A008-D8D7AB3D8178Q30596342-685041C3-FCC2-4C6B-982C-9368D94BE922Q31112248-FBA4252D-7FA8-4876-B146-37B289E6D460Q31112817-F2BF7217-AC44-4FC5-9214-AB55052B99BAQ32183014-34BA811C-D952-4EC4-B568-05416B7B6C95Q33407701-E8AC9BDB-F069-4909-A482-5805E1A77D64Q33526078-8053A2F8-026F-42C2-8014-9A93F9F02330Q33561637-D1593590-7426-43B0-946E-F8A912508CA7Q33613070-B7A5E149-7EDA-4056-84A0-2B228F2C3BC7Q33642335-2BCBEEA2-B782-4FE3-BCE1-4093D890231CQ33643957-0B10F9FC-F13B-44EA-9426-7257AD440445Q33650639-4895C63B-6013-4ABF-A399-01C1983F0B56Q33711371-5703810A-5118-4C3A-B7B4-F7CFDE982AC6Q33714515-12829810-3FEA-4D1B-93CE-67EDD18A90F8Q33784739-BD5E4D9E-54BF-43B8-8591-D40D7E163A7CQ33792824-F041B317-3AA9-43F7-938D-1D5DE1CFCE8EQ33869233-113ADD1A-EC8D-4BAA-AFFC-26A2011B81E9Q33875940-DE6B31E5-F9E2-4880-BF44-FD3274EB97F6Q33887291-4B8326FB-96C9-42FA-B076-717414053524Q33959824-5A2A2D56-FAFB-475D-96B8-C142A3D2FF8FQ33962426-F69D1DEE-C7D7-4DCE-B67A-4241AF2221C7
P2860
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Guideline for the management o ...... Ta, T1, and Tis): 2007 update.
@en
type
label
Guideline for the management o ...... Ta, T1, and Tis): 2007 update.
@en
prefLabel
Guideline for the management o ...... Ta, T1, and Tis): 2007 update.
@en
P2093
P1476
Guideline for the management o ...... Ta, T1, and Tis): 2007 update.
@en
P2093
Eila Curlee Skinner
Guido Dalbagni
J Stuart Wolf
John Derek Seigne
M Craig Hall
Paul F Schellhammer
Raj Som Pruthi
Sam S Chang
P304
P356
10.1016/J.JURO.2007.09.003
P407
P577
2007-12-01T00:00:00Z